Tebentafusp in Metastatic Uveal Melanoma
Survival rates are low in patients with metastatic uveal melanoma. Tebentafusp, a soluble bispecific protein, showed promise in a phase 2 study. A phase 3 study further assessed the overall survival benefit of tebentafusp. New research findings are summarized in a short video.
Copyright © 2021 Massachusetts Medical Society.
